Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2025—Pillar Biosciences announced it has finalized $34.5 million in funding, which includes a strategic investment from Illumina and structured financing from Soleus Capital, as well as investments from existing investors. The proceeds will be leveraged to advance commercial activities, including infrastructure to support biopharma partnerships, and expand adoption of its distributable clinical testing kits.
July 2025—Qiagen plans to launch three sample preparation instruments this year and next to expand its portfolio for automated sample preparation. QIAsymphony Connect, the next generation of the QIAsymphony, is progressing toward a phased launch to selected customers this year. The system, for in vitro diagnostic use, addresses pathogen nucleic acid extraction and other applications and can process up to 96 samples at a time. It features improved automation capabilities for sample tracking and new applications, higher yield for increase in assay sensitivity, and digital connectivity.
July 2025—Labcorp has expanded its precision oncology portfolio with its Labcorp Plasma Detect, to help assess the risk of disease recurrence in stage three colon cancer patients, and PGDx Elio Plasma Focus Dx, a kitted, pan-solid tumor liquid biopsy test authorized by the FDA to identify patients who may benefit from targeted treatments.
July 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.
July 2025—BD announced FDA 510(k) clearance for the BD Phoenix M50 automated microbiology solution and BDXpert system on the BD Synapsys informatics solution, leveraging rapid identification and antimicrobial susceptibility testing algorithms to assist in interpreting complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance. BDXpert is an automated, rule-based system that analyzes ID and AST results from the BD Phoenix M50 system.
July 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States. The AI-assisted screening tool is designed to help users locate, count, and preclassify parasites from iodine-stained fecal slides. The solution is part of Techcyte’s Fusion parasitology suite, which includes the company’s trichrome and modified acid fast solutions.
July 2025—BioMérieux has agreed to acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics. Day Zero Diagnostics, based in Watertown, Mass., has developed technologies that integrate direct from whole blood sample preparation, sequencing, and advanced infectious disease and antimicrobial susceptibility testing analytics. The sequencing-based rapid diagnostic in development can identify the species and antibiotic resistance profile of a bacterial pathogen within hours.
July 2025—Diasorin has received 510(k) clearance from the FDA for its Liaison Plex Gram-positive blood culture assay. The assay detects 17 targets (13 Gram-positive bacteria and four relevant resistance gene targets) in less than two hours and features Diasorin’s proprietary NanoGrid technology, which allows the detection of nucleic acids without the need for conventional amplification reactions.
June 2025—Beckman Coulter Diagnostics announced that its DxC 500i clinical analyzer received FDA 510(k) clearance. The integrated chemistry and immunoassay analyzer has a throughput of up to 800 clinical chemistry tests and 100 immunoassay tests per hour and features FlexMode operations, which prioritize immunoassay and chemistry testing according to each sample’s urgency.
June 2025—Qiagen announced the launch of its QIAprep& Plasmodium kit and two companion assays to support malaria research and surveillance efforts. The solution combines sample preparation and quantitative PCR into one workflow and detects all five Plasmodium species in human samples. The QIAprep& technology detects as little as one parasite per microliter, is compatible with liquid and dried blood samples, and is suitable for use on many qPCR platforms, including the company’s Rotor-Gene Q.
